Rethinking C. diff Treatment: Is Fidaxomicin Worth the Money?
The TAPER-V trial forces us to ask a question we should have been asking all along — would fidaxomicin have demonstrated superiority if the original trials had used longer follow-up?
Read more
Asundexian for Secondary Stroke Prevention OCEANIC-STROKE — A Three-Lens Critical Appraisal
OCEANIC-STROKE met its primary endpoint with a 26% relative reduction in ischemic stroke and no excess major bleeding — but the prespecified hierarchy broke at the 90-day endpoint. A statistician, a neurologist, and a researcher walk into a journal club. Here's what they each see.
Beyond Weight Loss: Reading the GLP-1 Side Effect Profile in Real Numbers A field guide for clinicians who are tired of being shown hazard ratios without denominators.
The Aspiration Anaerobe Myth What actually colonizes the aerodigestive tract — and why reflexive Zosyn for “possible aspiration” fails basic microbiology
